Vimarsana
Biggest News Aggregation in the World

Page 5 - Peter Lebowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Lebowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Lebowitz Today - Breaking & Trending Today

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Published: June 6, 2023

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...

Source: prnewswire.com
Related Topics:
United StatesHemophagocytic LymphohistiocytosisSatu GlawePeter LebowitzObrian KenneyData Monitoring CommitteeEuropean CommissionLegend Biotech United States IncEuropean Hematology AssociationJanssen Pharmaceutical CompaniesNone Of Janssen Research DevelopmentExchange CommissionDrug AdministrationAmerican Society Of Clinical OncologyJanssen Research DevelopmentJanssen Biotech IncJanssen Pharmaceutical Companies Of JohnsonCompanies Of JohnsonBiologics License ApplicationClinical OncologyAnnual MeetingHematology AssociationHybrid CongressGlobal Therapeutic Area HeadJanssen Research
Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Vimarsana News

Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Published: May 10, 2023

Johnson & Johnson will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA.... | May 10, 2023

Source: marketscreener.com
Related Topics:
Biljana NaumovicPeter LebowitzGoldman SachsAnnual Global Healthcare ConferenceWaldorf Astoria Monarch Beach ResortDana PointWorldwide Vice PresidentGlobal Therapeutic HeadEastern TimeJohnson Stock ExchangePress ReleaseAna Jnj Us4781601046
Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations - Vimarsana News

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

Published: April 21, 2023

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023

Source: marketscreener.com
Related Topics:
Region FlamandeUnited KingdomCity OfJanssen Cilag GmbMartin VogelMagda PalhotaPeter LebowitzGerhardt AttardJanssen Cilag GmUrology Care FoundationExchange CommissionDrug AdministrationCompanies Of JohnsonJanssen Research DevelopmentEuropean Medicines AgencyUniversity College LondonNone Of The Janssen Pharmaceutical CompaniesJanssen Pharmaceutical CompaniesTesaro IncEuropean CommissionJanssen Pharmaceutical Companies Of JohnsonDrug Administration Seeking Approval Of NiraparibEuropean UnionJanssen Cilag InternationalJanssen Biotech Inc
Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations - Vimarsana News

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

Published: April 21, 2023

News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com ... | April 21, 2023

Source: marketscreener.com
Related Topics:
United KingdomRegion FlamandeCity OfJanssen Cilag GmbPeter LebowitzMartin VogelMagda PalhotaGerhardt AttardEuropean CommissionUniversity College LondonCompanies Of JohnsonJanssen Cilag InternationalEuropean UnionDrug AdministrationJanssen Biotech IncTesaro IncJanssen Research DevelopmentJanssen Pharmaceutical Companies Of JohnsonNews ReleaseMarks First Approval WorldwideAbiraterone Acetate Dual Action TabletMetastatic Castration Resistant Prostate CancerJanssen Pharmaceutical CompaniesProfessor Gerhardt AttardArea Lead Oncology
NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer - Vimarsana News

NDA Submitted for Niraparib Plus Abiraterone Acetate + Prednisone for Prostate Cancer

Published: March 17, 2023

The NDA for niraparib plus abiraterone acetate and prednisone has been submitted to the FDA for patients with BRCA-positive mCRPC.

Source: oncologynurseadvisor.com
Related Topics:
Peter LebowitzDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical Companies Of JohnsonNew Drug ApplicationGlobal Therapeutic Area HeadJanssen ResearchJanssen Pharmaceutical CompaniesAccessed March